NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company specializing in surface acoustic wave (SAW) technology, has announced the renewal of its exclusive distribution agreement with Ultra Pain Products, Inc. (UPPI) for the distribution of the PainShield device. The five-year extension includes a minimum purchase commitment valued at $12 million, further solidifying the partnership between the two companies.
Brian Murphy, CEO of NanoVibronix, expressed his excitement about the extended partnership, stating, “We are thrilled to extend our partnership with Ultra Pain Products for another five years and secure a minimum purchase commitment of $12 million. UPPI’s remarkable growth, transition into manufacturing, and their focus on delivering affordable and effective solutions to patients align perfectly with our mission. They are an ideal partner to continue making a significant impact in non-opioid pain management.”
The renewal of the distribution agreement comes after a successful four-year collaboration, during which UPPI has grown substantially and become a leader in non-opioid pain management and injury recovery. UPPI’s commitment to providing effective alternatives to traditional pain treatments has led to its evolution as a key player in the industry. The agreement ensures that NanoVibronix’s PainShield, a portable ultrasound-based device, remains a key product in UPPI’s portfolio, offering non-invasive pain relief solutions.
Ari Alayev, President of Ultra Pain Products, commented on the renewal, saying, “We are honored to continue our exclusive distribution agreement with NanoVibronix. This partnership strengthens our mutual vision and trust, and we look forward to continuing to offer PainShield as part of our expanding range of innovative technologies. As we lead the charge in non-opioid treatments, this collaboration will further enhance our offerings to meet the growing demand for effective, non-invasive pain management solutions.”
The renewed partnership reflects the shared values of both companies, focusing on supporting injury recovery and providing patients with advanced, non-opioid therapeutic options. The PainShield device, which utilizes NanoVibronix’s patented low-intensity SAW technology, provides a safe and effective solution for pain relief without the need for prescription medication or continuous professional supervision. This makes it an ideal option for patients seeking alternatives to traditional pain management methods.
NanoVibronix is committed to advancing the field of non-opioid pain management through its innovative technologies, and this extended agreement with UPPI allows both companies to continue delivering groundbreaking solutions in the pain relief sector. The collaboration aims to address the growing demand for effective, non-addictive alternatives in pain treatment, providing patients with accessible and affordable options.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company based in Tyler, Texas, with research and development operations in Nesher, Israel. The company specializes in developing medical devices that utilize its proprietary low-intensity surface acoustic wave (SAW) technology. This technology generates low-frequency ultrasound waves that can be applied to a range of medical conditions, including pain relief and the disruption of biofilms and bacterial colonization. The company’s flagship products, PainShield® and UroShield®, are portable, easy-to-use devices designed for home use or in any healthcare setting.